Table 1 Baseline demographic and clinical characteristics with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV), within subgroups with pulmonary and non-pulmonary involvement at initial presentation of AAV
Patient characteristics | Pulmonary involvement | Non-pulmonary involvement |
|---|---|---|
(n = 59) | (n = 92) | |
Age, mean +/- SD years | 43 +/- 12.9 | 49 +/1 10.1 |
Male sex, n (%) | 29 (49) | 49 (53) |
AAV diagnosis, n (%) | ||
GPA | 38 (64.4) | 13 (14.1) |
MPA | 9 (15.3) | 49 (53.3) |
CS | 5 (8.5) | 4 (4.3) |
PAN | 4 (6.7) | 17 (18.5) |
Others | 3 (5.1) | 9 (9.8) |
Mean serum creatinine, uM (SD) | 176 +/- 139 | 251 +/- 161 |
ANCA positivity, n (%) | ||
MPO ANCA | 17 (29) | 58 (63) |
PR3 ANCA | 45 (76) | 41 (45) |
Relapses | 12 (20.3) | 25 (27) |
1-Relapse | 7 (11.8) | 15 (16.3) |
2-Relapse | 1 (1.7) | 3 (3.3) |
3-Relapse | 1 (1.7) | 3 (3.3) |
> 3-relapse | 3 (5.1) | 4 (4.3) |
Immunosuppressive therapy within 2 months of intial presentation, n (%) | ||
Cyclophosphamide | 26 (44) | 59 (62) |
Glucocorticoids | 29 (49) | 65 (70) |
Azathioprine | 3 (5) | 6 (6) |
Methotrexate | 8 (14) | 4 (4) |
Mycophenolate Mofetil | 0 (0) | 0 (0) |
Mean follow-up, years (SD) | 2.1 (2.9) | 2.24 (2.89) |
Deaths, n | 4 (6.8) | 4 (4.3) |